Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity

References

• Mohammed EMA. Multiple sclerosis is prominent in the Gulf states: review. Pathogenesis. 2016;3:19–38.
   Google Scholar
• Bohlega S, Inshasi J, Al Tahan AR, et al. Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol. 2013;260:2959–2963.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Nikanpour Y, Neshatfar A, et al. Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;40:101959.
   PubMed Web of Science ®Google Scholar
• Aljumah M, Alroughani R, Alsharoqi I, et al. Future of management of multiple sclerosis in the Middle East: a consensus view from specialists in ten countries. Mult Scler Int. 2013;2013:952321.
   PubMedGoogle Scholar
• Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2019;37:101459.
   PubMed Web of Science ®Google Scholar
• Bigaut K, De Seze J, Collongues N. Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2019;19:97–108.
   PubMed Web of Science ®Google Scholar
• Mavenclad. European Summary of Product Characteristics. [cited 2019 Aug]. Available from: https://www.medicines.org.uk/emc/product/8435
   Google Scholar
• Food and Drug Administration. Mavenclad (Cladribine). US Prescribing Information. [cited Aug 2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf
   Google Scholar
• European Medicines Agency. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. [cited Aug 2019]. Available from: https://www.ema.europa.eu/en/news/ema-confirms-recommendations-minimise-risk-brain-infection-pml-tysabri
   Google Scholar
• European Medicines Agency. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing. [cited Aug 2019]. Available from: https://www.ema.europa.eu/en/news/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing
   Google Scholar
• Vermersch P, Berger T, Gold R, et al. The clinical perspective: how to personalise treatment in MS and how may biomarkers including imaging contribute to this? Mult Scler. 2016;22(2 Suppl):18–33.
   PubMed Web of Science ®Google Scholar
• Alroughani R, Inshasi JS, Deleu D, et al. An overview of high-efficacy drugs for multiple sclerosis: Gulf region expert opinion. Neurol Ther. 2019;8:13–23.
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661.
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657–665.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285–294.
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504.
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73:705–713.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology. 1995;45:1268–1276.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Kappos L, et al. BG-12 increases the proportion of patients free of clinical and radiologic disease activity in relapsing-remitting multiple sclerosis: findings from the DEFINE study. Neurology. 2012;78(Suppl 1):PD5.005. Abstract. [cited Mar 2019]. Available from: https://n.neurology.org/content/78/1_Supplement/PD5.005
   Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–256.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–337.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al.; CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Arnold D, Bar-Or A, et al. Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies (PL02.004). Neurology. 2016;86(Suppl 1):Abstract PL02:004. [cited Aug 2019]. Available from: https://n.neurology.org/content/86/16_Supplement/PL02.004
   Google Scholar
• Vollmer B, Ontaneda D, Bandyopadhyay A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018;8:292–301.
   PubMedGoogle Scholar
• Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101–111.
   PubMed Web of Science ®Google Scholar
• European medicines Agency. Lemtrada. Measures to minimise risk of serious side effects of multiple sclerosis medicine. Press release. [cited Nov 2019]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada
   Google Scholar
• Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2:e158.
   PubMed Web of Science ®Google Scholar
• Galazka A, Nolting A, Cook S, et al. An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis (RMS). ECTRIMS Online Library. John V. 2017 Oct 27. 199898:P1878. Abstract. [cited 2019 June]. Available from: https://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/199898/vicky.john.an.analysis.of.malignancy.risk.in.the.clinical.development.html
   Google Scholar
• European Medicines Agency. Assessment Report. MAVENCLAD. International Non-Proprietary Name: Cladribine. Procedure No. EMEA/H/C/004230/0000. 2017 [cited Jan 2019]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004230/WC500234563.pdf
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2018. [cited Aug 2018]. Available from: https://www.whocc.no/atc_ddd_index
   Google Scholar
• Karussis D, Petrou P. Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale. Immunol Res. 2018;66:642–648.
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Immune reconstitution in MS: how does this impact treatment decisions? Medscape Educ. [cited Apr 2019]. Available from: http://img.medscapestatic.com/images/892/112/892112_transcript.pdf
   Google Scholar
• Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019 Mar 28;12:1756286419836913.
   Web of Science ®Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Assessment report EMA/435731/2017. Mavenclad, international non-proprietary name: cladribine. [cited Aug 2019]. Available from: https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf
   Google Scholar
• NHS England. Treatment algorithm for multiple sclerosis. disease-modifying therapies. Reference: 170079ALG. [cited Aug 2019]. Available from: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2019/03/Treatment-Algorithm-for-Multiple-Sclerosis-Disease-Modifying-Therapies-08-03-2019-1.pdf
   Google Scholar
• Charlson R, Herbert J, Kister I. CME/CNE ARTICLE: severity grading in multiple sclerosis: a proposal. Int J MS Care. 2016;18:265–270.
   PubMedGoogle Scholar
• Kuhle J, Kropshofer H, Haering DA, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92:e1007–e1015.
   PubMed Web of Science ®Google Scholar
• Braune S, Grimm S, van Hövell P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265:2980–2992.
   PubMed Web of Science ®Google Scholar
• Rammohan K, Giovannoni G, Comi G, et al. Cladribine tablets for relapsing-remitting multiple sclerosis: efficacy across patient subgroups from the phase III CLARITY study. Mult Scler Relat Disord. 2012;1:49–54.
   PubMed Web of Science ®Google Scholar
• Berardi A, Siddiqui MK, Treharne C, et al. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Curr Med Res Opin. 2019;35:1371–1378.
   PubMed Web of Science ®Google Scholar
• Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19:106–114.
   PubMedGoogle Scholar
• Giovannoni G, Hawkes C, Waubant E, et al. The ‘field hypothesis’: rebound activity after stopping disease-modifying therapies. Mult Scler Relat Disord. 2017;15:A1–A2.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA warns about severe worsening of multiple sclerosis after stopping the medicine Gilenya (fingolimod). Safety announcement. [cited Aug 2019]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-severe-worsening-multiple-sclerosis-after-stopping-medicine-gilenya-fingolimod
   Google Scholar
• Río J, Rovira À, Tintoré M, et al. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler. 2018;24:322–330.
   PubMed Web of Science ®Google Scholar
• van der Vuurst de Vries RM1, Mescheriakova JY1, Wong YYM, et al. Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol. 2018;75:1392–1398.
   PubMed Web of Science ®Google Scholar
• Schwenkenbecher P, Wurster U, Konen FF, et al. Impact of the McDonald criteria 2017 on early diagnosis of relapsing-remitting multiple sclerosis. Front Neurol. 2019;10:188.
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120.
   PubMed Web of Science ®Google Scholar
• Miller AE, Vermersch P, Kappos L, et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: results of the TOPIC extension study. Mult Scler Relat Disord. 2019;33:131–138.
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014t;13:977–986.
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–1511.
   PubMed Web of Science ®Google Scholar
• Montalban X, Leist TP, Cohen BA, et al. Cladribine tablets added to IFN-β in active relapsing MS: the ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018;5:e477.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Hardmeier M, Disanto G, et al. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis. Mult Scler. 2016;22:533–543.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–220.
   PubMed Web of Science ®Google Scholar